Rush’s history of research excellence attracts some of the most innovative minds in medicine.
Rush scientists were the first to determine the causes of scarlet fever and heart attacks. They also discovered sickle cell anemia and developed one of the world’s first implantable pacemakers.
Today, Rush continues to spearhead research at the national level for diseases from Alzheimer’s to osteoarthritis to AIDS. Rush is involved in more than 1,600 research studies, including trials of new medical and surgical therapies. Rush is a research leader in neurosciences, cancer, immunology, inflammation, infection and regenerative medicine. And Rush continues to receive increases in NIH research funding for our research studies.
Rush is also leading research in the use of information technologies to improve health care. We are a member of the Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN) — a data-transfer infrastructure that supports the sharing and analysis of information on more than one million Chicago-area patients, potentially restructuring the nation’s patient research landscape. Rush is also partnering with Tempus, a technology company focused on helping doctors personalize cancer care. Using machine learning and advanced bioinformatics, Tempus provides genomic sequencing services and analyzes molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. At Rush, we are committed to innovation and, through our partnership with Tempus, we expect to be able to usher in an unprecedented era of advancement as it relates to doing what is and has always been first and foremost at Rush: caring for our patients.
Tomorrow holds that same promise for you. Rush is spearheading research at the national level. Explore opportunities with us to conduct research at the level of excellence you aspire to reach.
Rush is involved in more than 1,600 research studies.
Rush partners with the technology company Tempus to house a biorepository of cancer patients’ tissue samples. This project builds on Rush’s existing partnership, which provides genetic analyses of cancer patients to help drive treatment decisions.